Hims & Hers Faces Dual Challenge: Legal Scrutiny and Operational Shift

Hims & Hers navigates a board investigation and margin pressure after discontinuing its compounded GLP-1 drug, despite reporting strong Q4 2025 revenue and subscriber growth.

The telehealth company Hims & Hers Health, Inc. finds itself navigating a complex landscape of legal and operational pressures. Recent developments, including the withdrawal of a key product and the launch of a board investigation, are prompting investors to question the sustainability of its otherwise strong growth trajectory.

Legal Investigation Follows Product Discontinuation

A new source of uncertainty has emerged from the legal sector. The Law Offices of Howard G. Smith announced it is examining potential breaches of fiduciary duty by members of the Hims & Hers board of directors. This probe was triggered directly by the company's decision to halt sales of its self-manufactured, or "compounded," version of the weight-loss medication Wegovy.

The move to discontinue the product came after public criticism from a former commissioner of the U.S. Food and Drug Administration (FDA). The ex-official raised concerns about the underlying technology and highlighted a lack of clinical trial data, which subsequently increased regulatory and public scrutiny. This environment provided the foundation for the newly initiated legal examination.

Strong Quarterly Results Tempered by Cautious Guidance

The company's financial report for the fourth quarter of 2025 presented a mixed picture for the market. On one hand, performance metrics were robust. Revenue saw a significant year-over-year increase, reaching $617.8 million. Furthermore, the subscriber base expanded to over 2.51 million customers. The company even surpassed market expectations for earnings per share, reporting $0.08, and its adjusted EBITDA also improved compared to the previous year.

However, management's forward-looking statements moderated investor enthusiasm. For the first quarter of 2026, revenue guidance was set between $600 million and $625 million, a range that fell short of some analyst projections. For the full 2026 fiscal year, the company is targeting revenue of $2.7 billion to $2.9 billion, with an adjusted EBITDA forecast of $300 million to $375 million. In a climate of heightened uncertainty, the market's focus often shifts from past achievements to the company's ability to maintain its growth momentum in upcoming quarters.

Profitability Metrics Show Strain

Alongside the guidance, profitability came into sharper focus. The most recent reporting period revealed a contraction in the gross margin, which declined by 500 basis points to 72%. Analysts link this pressure directly to the discontinuation of the compounded GLP-1 product line, a decision that followed criticism from the FDA and a lawsuit filed by Novo Nordisk.

The tense situation is clearly reflected in the equity's performance. The stock recently closed at €12.28, a price that simultaneously marked a new 52-week low.

The central question now facing Hims & Hers is whether it can operationally offset the gap left by the discontinued GLP-1 business without further compromising its margin profile and growth rate. This operational challenge is now compounded by the additional uncertainty introduced by the announced legal investigation into the board's conduct.